NLNK stock forecast
Our latest prediction for NewLink Genetics Corp.'s stock price was made on the Nov. 21, 2017 when the stock price was at 8.58$.
In the short term (2weeks), NLNK's stock price should underperform the market by -0.14%. During that period the price should oscillate between -9.25% and +12.80%.
In the medium term (3months), NLNK's stock price should underperform the market by -0.82%. During that period the price should oscillate between -20.42% and +31.29%.Get email alerts
Create a solid portfolio with NLNK
About NewLink Genetics Corp.
NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
At the moment the company generates 22M USD in revenues.
On its last earning announcement, the company reported a loss of -1.48$ per share.
The book value per share is 3.36$
Three months stock forecastNov. 21, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|